Heart failure
Conditions
Interventions
Control group:standard heart failure therapy
Experimental group:standard heart failure therapy combined with levosimendan and dopamine
Sponsors
The First Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients over 18 years old with definite diagnosis of congestive heart failure, regardless of gender, sign informed consent; 2. In patients with NYHA grade III - IV, EF <= 40%; 3. Patients with systolic blood pressure <= 100mmhg; 4. Patients who received routine treatment (such as diuretics, ACEI, ARB, Arni, digitalis, etc.) but had poor effect.
Exclusion criteria
Exclusion criteria: 1. Patients with severe electrolyte disorder; 2. Patients with severe liver or renal insufficiency, EGFR < 30 ml / min / 1.73 M2 (MDRD formula), or severe hematological diseases; 3. Patients with malignant arrhythmia events in recent 3 months; 4. Pregnant or lactating women; 5. The subjects who are allergic to levosimendan or have used levosimendan within 30 days; 6. Those who have participated in other clinical trials within 30 days or whose data are incomplete or who are unwilling to participate in this project.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of MACE;improvement of cardiac function; | — |
Secondary
| Measure | Time frame |
|---|---|
| average hospitalization days;average hospitalization cost;cognitive function; | — |
Countries
China
Contacts
Public ContactYuedong Ma
The First Affiliated Hospital of Sun Yat-Sen University
Outcome results
None listed